Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001213900-25-044477
Filing Date
2025-05-15
Accepted
2025-05-15 18:53:25
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6809
  Complete submission text file 0001213900-25-044477.txt   8538
Mailing Address C/O ONCORE BIOPHARMA, INC. 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address
Ramaswamy Vivek (Filed by) CIK: 0001635075 (see all company filings)

Type: SCHEDULE 13G/A

Mailing Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB
Business Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB 441-295-5950
Roivant Sciences Ltd. (Subject) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-93291 | Film No.: 25956442
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)